EUVIMEDEUVIMED entdecken
Übersichtsarbeit

A comprehensive review of immune checkpoint inhibitors for cancer treatment

Md Arafat Hossain

International Immunopharmacology · 2024-12 · 143 · 113365

DOI: 10.1016/j.intimp.2024.113365 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Immunopharmacology, 2024-12. Verfasst von Md Arafat Hossain. Beteiligte Einrichtung: Department of Pharmacy, Bangabandhu Sheikh Mujibur Rahman Science and Technology University, Gopalganj 8100, Bangladesh. Electronic address: mdarafat…. Hauptthemen laut MEDLINE: Neoplasms, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 199-mal zitiert (Crossref) und nennt 617 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immunology-based therapies are emerging as an effective cancer treatment, using the body's immune system to target tumors. Immune checkpoints, which regulate immune responses to prevent tissue damage and autoimmunity, are often exploited by cancer cells to avoid destruction. The discovery of checkpoint proteins like PD-1/PD-L1 and CTLA-4 was pivotal in developing cancer immunotherapy. Immune checkpoint inhibitors (ICIs) have shown great success, with FDA-approved drugs like PD-1 inhibitors (Nivolumab, Pembrolizumab, Cemiplimab), PD-L1 inhibitors (Atezolizumab, Durvalumab, Avelumab), and CTLA-4 inhibitors (Ipilimumab, Tremelimumab), alongside LAG-3 inhibitor Relatlimab. Research continues on new checkpoints like TIM-3, VISTA, B7-H3, BTLA, and TIGIT. Biomarkers like PDL-1 expression, tumor mutation burden, interferon-γ presence, microbiome composition, and extracellular matrix characteristics play a crucial role in predicting responses to immunotherapy with checkpoint inhibitors. Despite their effectiveness, not all patients experience the same level of benefit, and organ-specific immune-related adverse events (irAEs) such as rash or itching, colitis, diarrhea, hyperthyroidism, and hypothyroidism may occur. Given the rapid advancements in this field and the variability in patient outcomes, there is an urgent need for a comprehensive review that consolidates the latest findings on immune checkpoint inhibitors, covering their clinical status, biomarkers, resistance mechanisms, strategies to overcome resistance, and associated adverse effects. This review aims to fill this gap by providing an analysis of the current clinical status of ICIs, emerging biomarkers, mechanisms of resistance, strategies to enhance therapeutic efficacy, and assessment of adverse effects. This review is crucial to furthering our understanding of ICIs and optimizing their application in cancer therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsImmune Checkpoint InhibitorsHumansAnimalsImmunotherapy

Stichwörter der Autor:innen

BiomarkersImmune checkpoint inhibitorsImmune-related adverse effectsImmuno-oncologyPD-1/PDL-1 and CTLA-4Resistance mechanisms and overcome

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Pharmacy, Bangabandhu Sheikh Mujibur Rahman Science and Technology University, Gopalganj 8100, Bangladesh. Electronic address: mdarafathossain745@gmail.com.

Zitieren

APA

Arafat Hossain, M. (2024). A comprehensive review of immune checkpoint inhibitors for cancer treatment. International Immunopharmacology, 143, 113365. https://doi.org/10.1016/j.intimp.2024.113365

Vancouver

Arafat Hossain M. A comprehensive review of immune checkpoint inhibitors for cancer treatment. International Immunopharmacology. 2024;143:113365. doi:10.1016/j.intimp.2024.113365

BibTeX
@article{ArafatHossain2024,
  author = {Arafat Hossain, Md},
  title = {A comprehensive review of immune checkpoint inhibitors for cancer treatment},
  journal = {International Immunopharmacology},
  year = {2024},
  volume = {143},
  pages = {113365},
  doi = {10.1016/j.intimp.2024.113365}
}
Kostenlos starten →